Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

26.48 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
33 34 Next >
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. 
Via Benzinga
Stock Market Round-Up: Rivian Rides High, Meta Platforms Makes Moves, And Tesla Ticks Up
Via Benzinga
Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results
Cassava Sciences (SAVA) stock is down 11% on underwhelming results from its Phase 3 clinical trials for its Alzheimer's treatment. 
Via InvestorPlace
Why Cassava Sciences Stock Is Trading Down Today
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Shares of Cassava Sciences Are Dropping Wednesday
The company announced phase 3 trial results for its lead Alzheimer's therapy. 
Via The Motley Fool
Why Shares of Cassava Sciences Jumped This Week
Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam. 
Via The Motley Fool
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
Today, shareholders in Cassava Sciences and SAVA stock are cheering some positive research data for its key drug candidate. 
Via InvestorPlace
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
Dow, S&P 500 Move Lower On Renewed Fed Fatigue
Stocks are moving lower ahead of the Federal Reserve's June meeting minutes, which are due out this afternoon. 
Via Talk Markets
Promising Alzheimer's Treatment: Cassava Sciences' Simufilam Slows Cognitive Decline by 38% in Clinical Study
Cassava Sciences Inc (NASDAQ: SAVA) announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus... 
Via Benzinga
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
New Research Shows Simufilam Suppresses Overactive mTOR
From Cassava Sciences, Inc.
Via GlobeNewswire
New Publication Highlights Basic Science Supporting Simufilam
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
3 Biotech Stocks to Avoid Like the Plague
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Hero or Zero? 7 High-Risk Stocks to Make You Rich… Or Broke.
These seven high-risk stocks could ultimately rocket to the moon, or fall to the depths of the stock market graveyard. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Why Is Asana (ASAN) Stock Up 24% Today?
Asana (ASAN) stock is on the rise Thursday as investors react to the CEO share purchase plans and its latest earnings report. 
Via InvestorPlace
ETSY Stock Falls on Double Downgrade
Etsy (ETSY) stock is falling on Thursday after the e-commerce company's shares were hit with a double downgrade from Jefferies. 
Via InvestorPlace
3 Short-Squeeze Stocks to Keep on Your Radar
These three short-squeeze stocks are each options investors may want to consider as companies with near-term catalysts that could run. 
Via InvestorPlace
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule. 
Via InvestorPlace
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.